Interesting read from a SA article on NanoString:
"Prostate Cancer Prognostic Test
CytoDyn Inc. (OTCQB:CYDY) has a prostate cancer prognostic test that might be an ideal match to expand NSTG's product offering. There is no formally announced partnership between the two companies. All that is known is the CYDY used NSTG's equipment to develop a prognostic test in prostate cancer and that they are filing a 510(k) with the FDA this year and planning on a licensing deal in the 1H 2019. CYDY has the intellectual property for detecting the aggressive form of prostate cancer. The test uses NSTG's technology to check the patient's biopsy for a specific aggressive prostate cancer gene signature. Removing a prostate has unwanted side effects of erectile dysfunction, incontinence, and dribbling. Since most prostate cancer is slow growing, removal is not indicated.
However, missing the presence for the aggressive form has serious consequences. The PSA test has many problems such as; false positives and not distinguishing between the slow and aggressive types of cancer. The current prostate cancer tests, besides the standard Gleason score is estimated by CYDY to cost about $3,500, but they really don't give actionable data. For example, the current tests (in the slide above) check whether or not the patient has the aggressive form of prostate cancer. If the patient tests negative the for the aggressive form, the patient has a 90% chance of living 10 years, but if the patient tests positive he has an 80% chance of living 10 years. The test doesn't give a definitive answer of whether or not to remove the prostate. CYDY's test using the NSTG array, really gives the patient actionable data. For example, if the patient tests negative he has a 80% chance of living 10 years. If the patient tests positive for the aggressive prostate cancer there is a 100% chance he is going to die in 5 years. This is highlighted in the slide above. The decision is more black and white for the patient. CYDY has been very vocal about being in the final stages of a licensing deal with a potential partner. The amount and timing of the cash raise by NSTG seem to fit. CYDY estimates the potential market for the prostate cancer prognostic test is $750 million annually assuming 220,800 new cases of prostate cancer annually."
"Prostate Cancer Prognostic Test
CytoDyn Inc. (OTCQB:CYDY) has a prostate cancer prognostic test that might be an ideal match to expand NSTG's product offering. There is no formally announced partnership between the two companies. All that is known is the CYDY used NSTG's equipment to develop a prognostic test in prostate cancer and that they are filing a 510(k) with the FDA this year and planning on a licensing deal in the 1H 2019. CYDY has the intellectual property for detecting the aggressive form of prostate cancer. The test uses NSTG's technology to check the patient's biopsy for a specific aggressive prostate cancer gene signature. Removing a prostate has unwanted side effects of erectile dysfunction, incontinence, and dribbling. Since most prostate cancer is slow growing, removal is not indicated.
However, missing the presence for the aggressive form has serious consequences. The PSA test has many problems such as; false positives and not distinguishing between the slow and aggressive types of cancer. The current prostate cancer tests, besides the standard Gleason score is estimated by CYDY to cost about $3,500, but they really don't give actionable data. For example, the current tests (in the slide above) check whether or not the patient has the aggressive form of prostate cancer. If the patient tests negative the for the aggressive form, the patient has a 90% chance of living 10 years, but if the patient tests positive he has an 80% chance of living 10 years. The test doesn't give a definitive answer of whether or not to remove the prostate. CYDY's test using the NSTG array, really gives the patient actionable data. For example, if the patient tests negative he has a 80% chance of living 10 years. If the patient tests positive for the aggressive prostate cancer there is a 100% chance he is going to die in 5 years. This is highlighted in the slide above. The decision is more black and white for the patient. CYDY has been very vocal about being in the final stages of a licensing deal with a potential partner. The amount and timing of the cash raise by NSTG seem to fit. CYDY estimates the potential market for the prostate cancer prognostic test is $750 million annually assuming 220,800 new cases of prostate cancer annually."
